Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: Oncogene. 2011 Oct 24;31(25):3039–3050. doi: 10.1038/onc.2011.474

Figure 5.

Figure 5

PTEN re-expression in GBM tumor cells does not confer sensitivity to EGFR kinase inhibition. (a) Schematic representation of the pSLIK-PTEN lentiviral vector for Tet-inducible expression of PTEN. The original pSLIK vector (Shin et al., 2006; Zhu et al., 2007) was modified to confer blasticidine resistance as described in Supplementary Information. (b) Immunoblot analysis of total cell lysates from PTEN deficient GBM tumor cell cultures (T4 & T5) re-expressing PTEN probed for cleaved PARP. Control cultured cells sensitive to gefitinib-induced apoptosis are derived from a TGFα-EGFRWT;InkΔ2/3−/− tumor. (c) Graphical representation of flow cytometry analysis of cleaved caspase-3 in PTEN deficient and isogenic PTEN re-expressing GBM tumor cell cultures (T4 & T5) (mean ± SD; n=3 in each group).